In the original article, there was a mistake in Figure 1 and its caption as published. The label for group 4 in Figure 1A is misspelled, it is supposed to be “LPS+SVHRP” instead of “LPS+SVHRSP”. Furthermore, in the caption for Figure 1, the description for Figure 1E was missing, which is the quantification result for the immunoblotting shown in (D). The correct Figure 1 and caption appear below.
FIGURE 1
SVHRP inhibits inflammagen-induced microglia activation and inflammatory response in hippocampus. Mice were injected with SVHRP (LPS + SVHRP or SVHRP group, 125 µg/5 ml/kg, i.p.) or NS (LPS or CTRL group, 1 ml/kg, i.p.) for 3 days before and 1 day after LPS treatment (5 mg/kg, i.p.) before the mouse brains were harvested for immuno-staining for Iba-1. (A) Representative images of Iba-1 staining (IF staining, upper three panels and IHC staining, lower two panels) in hippocampus were demonstrated. (B) The average percent area of Iba-1 positive staining of four groups was analyzed using the images from IHC staining. (C) mRNA expressions of TNF-α and iNOS from hippocampus were measured by real-time PCR and calculated using 2−ΔΔCT method with GAPDH as the internal reference gene. The expression of iNOS protein from hippocampus was assessed by western blot. (D) Representative blot for iNOS and (E) quantification of iNOS protein normalized to β-actin. The data were expressed as the means ± SEM (n ≥ 3 for each group). #p < 0.05 compared with CTRL group, *p < 0.05 compared with LPS group.
Additionally, there was a mistake in the caption for Figure 2 as published. In Figure 2, the value of the Bar in Figures 2A–C, a is supposed to be 50 instead of 20 μm. The correct Figure 2 appears below.
FIGURE 2
SVHRP attenuates LPS-induced upregulation of Iba-1 in microglia. IF staining for Iba-1 in primary neuron-glia (A), mixed glia (B), and enriched microglia (C) cultures were performed 24 h after LPS treatment. Cells were pretreated with vehicle or SVHRP (20 μg/ml) for 1 h before LPS challenge. (a) Representative images of Iba-1 positive cells (400×, Bar = 50 μm). (b) Cell number and average grey scale for Iba-1 staining were shown. The data were the means ± SEM (n ≥ 3 for each cell preparation). #p < 0.05 compared with CTRL group, *p < 0.05 compared with LPS group.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Statements
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Summary
Keywords
SVHRP, anti-inflammation, microglia, NF-κB, MAPKs
Citation
Wu X-F, Li C, Yang G, Wang Y-Z, Peng Y, Zhu D-D, Sui A-R, Wu Q, Li Q-F, Wang B, Li N, Zhang Y, Ge B-Y, Zhao J and Li S (2021) Corrigendum: Scorpion Venom Heat-Resistant Peptide Attenuates Microglia Activation and Neuroinflammation. Front. Pharmacol. 12:791953. doi: 10.3389/fphar.2021.791953
Received
09 October 2021
Accepted
05 November 2021
Published
26 November 2021
Volume
12 - 2021
Edited and reviewed by
Massimo Grilli, University of Genoa, Italy
Updates
Copyright
© 2021 Wu, Li, Yang, Wang, Peng, Zhu, Sui, Wu, Li, Wang, Li, Zhang, Ge, Zhao and Li.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Shao Li, lishao89@dmu.edu.cn; Jie Zhao, dlzhaoj@163.com
†These authors have contributed equally to this work
This article was submitted to Neuropharmacology, a section of the journal Frontiers in Pharmacology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.